Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial
The study aims to assess the cost-effectiveness of a personalised telehealth intervention to manage chronic disease in the long run. The Personalised Health Care (PHC) pilot study was a randomised trial with an economic evaluation alongside over 12 months. From a health service perspective, the prim...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-06, Vol.18 (6), p.e0286533-e0286533 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0286533 |
|---|---|
| container_issue | 6 |
| container_start_page | e0286533 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Mudiyanselage, Shalika Bohingamu Stevens, Jo Toscano, Julian Kotowicz, Mark A Steinfort, Christopher L Hayles, Robyn Watts, Jennifer J |
| description | The study aims to assess the cost-effectiveness of a personalised telehealth intervention to manage chronic disease in the long run.
The Personalised Health Care (PHC) pilot study was a randomised trial with an economic evaluation alongside over 12 months. From a health service perspective, the primary analysis compared the costs and effectiveness of PHC telehealth monitoring with usual care. An incremental cost-effectiveness ratio was calculated based on costs and health-related quality of life. The PHC intervention was implemented in the Barwon Health region, Geelong, Australia, for patients with a diagnosis of COPD and/or diabetes who had a high likelihood of hospital readmission over 12 months.
When compared to usual care at 12 months, the PHC intervention cost AUD$714 extra per patient (95%CI -4879; 6308) with a significant improvement of 0.09 in health-related quality of life (95%CI: 0.05; 0.14). The probability of PHC being cost-effective by 12 months was close to 65%, at willingness to pay a threshold of AUD$50,000 per quality-adjusted life year.
Benefits of PHC to patients and the health system at 12 months translated to a gain in quality-adjusted life years with a non-significant cost difference between the intervention and control groups. Given the relatively high set-up costs of the PHC intervention, the program may need to be offered to a larger population to achieve cost-effectiveness. Long-term follow-up is required to assess the real health and economic benefits over time. |
| doi_str_mv | 10.1371/journal.pone.0286533 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2826187450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A753093984</galeid><doaj_id>oai_doaj_org_article_6c1d1924f89a4202aa884413f4b7e74c</doaj_id><sourcerecordid>A753093984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c642t-5c9e13f8bf5e00c316360c97b2231808714023041addae6a89e3c6fa6a57cb413</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QLgujFjPlq2nojw-DHwMKCX7chk57MZEib2SRd9MbfbjrTXaayF5KLhOQ570nek5NlzzGaY1ridzvX-07a-d51MEek4gWlD7JzXFMy4wTRhyfrs-xJCDuEClpx_jg7oyXFNanRefZn6UKcgdagormBDkLInc734INL6iZAk0ewsAVp4zY3XQSfsGhcl2vnc7X1rjMqbxIpA-St7OQG2kS8zxf53lgXcy-7xrUHKeW66J21g6o30j7NHmlpAzwb54vsx6eP35dfZpdXn1fLxeVMcUbirFA1YKqrtS4AIUUxpxypulwTQnGFqhIzRChiWDaNBC6rGqjiWnJZlGrNML3IXh5199YFMVoXBKkIx1XJCpSI1ZFonNyJvTet9L-Fk0YcNpzfCOmjURYEV7hJ9jFd1ZIRRKSsKpaSaLYuoWQqaX0Ys_XrFhqV3PDSTkSnJ53Zio27ERiREnHMksKbUcG76x5CFMk_BdbKDlx_uHhJCs75gL76B73_eSO1kekFptMuJVaDqFiUBUU1ratBa34PlUYDrUm1A23S_iTg7SRgqC_8ihvZhyBW377-P3v1c8q-PmGPny842w__LkxBdgSVdyF40HcuYySGPrl1Qwx9IsY-SWEvTit0F3TbGPQvpAwO6Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2826187450</pqid></control><display><type>article</type><title>Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Mudiyanselage, Shalika Bohingamu ; Stevens, Jo ; Toscano, Julian ; Kotowicz, Mark A ; Steinfort, Christopher L ; Hayles, Robyn ; Watts, Jennifer J</creator><contributor>Tsuzuki, Shinya</contributor><creatorcontrib>Mudiyanselage, Shalika Bohingamu ; Stevens, Jo ; Toscano, Julian ; Kotowicz, Mark A ; Steinfort, Christopher L ; Hayles, Robyn ; Watts, Jennifer J ; Tsuzuki, Shinya</creatorcontrib><description>The study aims to assess the cost-effectiveness of a personalised telehealth intervention to manage chronic disease in the long run.
The Personalised Health Care (PHC) pilot study was a randomised trial with an economic evaluation alongside over 12 months. From a health service perspective, the primary analysis compared the costs and effectiveness of PHC telehealth monitoring with usual care. An incremental cost-effectiveness ratio was calculated based on costs and health-related quality of life. The PHC intervention was implemented in the Barwon Health region, Geelong, Australia, for patients with a diagnosis of COPD and/or diabetes who had a high likelihood of hospital readmission over 12 months.
When compared to usual care at 12 months, the PHC intervention cost AUD$714 extra per patient (95%CI -4879; 6308) with a significant improvement of 0.09 in health-related quality of life (95%CI: 0.05; 0.14). The probability of PHC being cost-effective by 12 months was close to 65%, at willingness to pay a threshold of AUD$50,000 per quality-adjusted life year.
Benefits of PHC to patients and the health system at 12 months translated to a gain in quality-adjusted life years with a non-significant cost difference between the intervention and control groups. Given the relatively high set-up costs of the PHC intervention, the program may need to be offered to a larger population to achieve cost-effectiveness. Long-term follow-up is required to assess the real health and economic benefits over time.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0286533</identifier><identifier>PMID: 37319290</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Biology and Life Sciences ; Care and treatment ; Chronic diseases ; Chronic illnesses ; Chronic obstructive pulmonary disease ; Clothing industry ; Comparative analysis ; Cost analysis ; Cost control ; Costs ; Customization ; Diabetes ; Diabetes mellitus ; Diagnosis related groups ; Disease management ; DRGs ; Economic analysis ; Economic aspects ; Effectiveness ; Emergency medical care ; Engineering and Technology ; Evaluation ; Health care expenditures ; Health services ; Hospital costs ; Hospitalization ; Intervention ; Lung diseases, Obstructive ; Medical care, Cost of ; Medicine and Health Sciences ; Patient admissions ; Patient outcomes ; Patients ; Quality of life ; Social Sciences ; Software ; Telemedicine</subject><ispartof>PloS one, 2023-06, Vol.18 (6), p.e0286533-e0286533</ispartof><rights>Copyright: © 2023 Mudiyanselage et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Mudiyanselage et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Mudiyanselage et al 2023 Mudiyanselage et al</rights><rights>2023 Mudiyanselage et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c642t-5c9e13f8bf5e00c316360c97b2231808714023041addae6a89e3c6fa6a57cb413</cites><orcidid>0000-0001-8095-8638 ; 0000-0003-1090-4401</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270614/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270614/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37319290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tsuzuki, Shinya</contributor><creatorcontrib>Mudiyanselage, Shalika Bohingamu</creatorcontrib><creatorcontrib>Stevens, Jo</creatorcontrib><creatorcontrib>Toscano, Julian</creatorcontrib><creatorcontrib>Kotowicz, Mark A</creatorcontrib><creatorcontrib>Steinfort, Christopher L</creatorcontrib><creatorcontrib>Hayles, Robyn</creatorcontrib><creatorcontrib>Watts, Jennifer J</creatorcontrib><title>Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The study aims to assess the cost-effectiveness of a personalised telehealth intervention to manage chronic disease in the long run.
The Personalised Health Care (PHC) pilot study was a randomised trial with an economic evaluation alongside over 12 months. From a health service perspective, the primary analysis compared the costs and effectiveness of PHC telehealth monitoring with usual care. An incremental cost-effectiveness ratio was calculated based on costs and health-related quality of life. The PHC intervention was implemented in the Barwon Health region, Geelong, Australia, for patients with a diagnosis of COPD and/or diabetes who had a high likelihood of hospital readmission over 12 months.
When compared to usual care at 12 months, the PHC intervention cost AUD$714 extra per patient (95%CI -4879; 6308) with a significant improvement of 0.09 in health-related quality of life (95%CI: 0.05; 0.14). The probability of PHC being cost-effective by 12 months was close to 65%, at willingness to pay a threshold of AUD$50,000 per quality-adjusted life year.
Benefits of PHC to patients and the health system at 12 months translated to a gain in quality-adjusted life years with a non-significant cost difference between the intervention and control groups. Given the relatively high set-up costs of the PHC intervention, the program may need to be offered to a larger population to achieve cost-effectiveness. Long-term follow-up is required to assess the real health and economic benefits over time.</description><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Chronic diseases</subject><subject>Chronic illnesses</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clothing industry</subject><subject>Comparative analysis</subject><subject>Cost analysis</subject><subject>Cost control</subject><subject>Costs</subject><subject>Customization</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diagnosis related groups</subject><subject>Disease management</subject><subject>DRGs</subject><subject>Economic analysis</subject><subject>Economic aspects</subject><subject>Effectiveness</subject><subject>Emergency medical care</subject><subject>Engineering and Technology</subject><subject>Evaluation</subject><subject>Health care expenditures</subject><subject>Health services</subject><subject>Hospital costs</subject><subject>Hospitalization</subject><subject>Intervention</subject><subject>Lung diseases, Obstructive</subject><subject>Medical care, Cost of</subject><subject>Medicine and Health Sciences</subject><subject>Patient admissions</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Social Sciences</subject><subject>Software</subject><subject>Telemedicine</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QLgujFjPlq2nojw-DHwMKCX7chk57MZEib2SRd9MbfbjrTXaayF5KLhOQ570nek5NlzzGaY1ridzvX-07a-d51MEek4gWlD7JzXFMy4wTRhyfrs-xJCDuEClpx_jg7oyXFNanRefZn6UKcgdagormBDkLInc734INL6iZAk0ewsAVp4zY3XQSfsGhcl2vnc7X1rjMqbxIpA-St7OQG2kS8zxf53lgXcy-7xrUHKeW66J21g6o30j7NHmlpAzwb54vsx6eP35dfZpdXn1fLxeVMcUbirFA1YKqrtS4AIUUxpxypulwTQnGFqhIzRChiWDaNBC6rGqjiWnJZlGrNML3IXh5199YFMVoXBKkIx1XJCpSI1ZFonNyJvTet9L-Fk0YcNpzfCOmjURYEV7hJ9jFd1ZIRRKSsKpaSaLYuoWQqaX0Ys_XrFhqV3PDSTkSnJ53Zio27ERiREnHMksKbUcG76x5CFMk_BdbKDlx_uHhJCs75gL76B73_eSO1kekFptMuJVaDqFiUBUU1ratBa34PlUYDrUm1A23S_iTg7SRgqC_8ihvZhyBW377-P3v1c8q-PmGPny842w__LkxBdgSVdyF40HcuYySGPrl1Qwx9IsY-SWEvTit0F3TbGPQvpAwO6Q</recordid><startdate>20230615</startdate><enddate>20230615</enddate><creator>Mudiyanselage, Shalika Bohingamu</creator><creator>Stevens, Jo</creator><creator>Toscano, Julian</creator><creator>Kotowicz, Mark A</creator><creator>Steinfort, Christopher L</creator><creator>Hayles, Robyn</creator><creator>Watts, Jennifer J</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8095-8638</orcidid><orcidid>https://orcid.org/0000-0003-1090-4401</orcidid></search><sort><creationdate>20230615</creationdate><title>Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial</title><author>Mudiyanselage, Shalika Bohingamu ; Stevens, Jo ; Toscano, Julian ; Kotowicz, Mark A ; Steinfort, Christopher L ; Hayles, Robyn ; Watts, Jennifer J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c642t-5c9e13f8bf5e00c316360c97b2231808714023041addae6a89e3c6fa6a57cb413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Chronic diseases</topic><topic>Chronic illnesses</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clothing industry</topic><topic>Comparative analysis</topic><topic>Cost analysis</topic><topic>Cost control</topic><topic>Costs</topic><topic>Customization</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diagnosis related groups</topic><topic>Disease management</topic><topic>DRGs</topic><topic>Economic analysis</topic><topic>Economic aspects</topic><topic>Effectiveness</topic><topic>Emergency medical care</topic><topic>Engineering and Technology</topic><topic>Evaluation</topic><topic>Health care expenditures</topic><topic>Health services</topic><topic>Hospital costs</topic><topic>Hospitalization</topic><topic>Intervention</topic><topic>Lung diseases, Obstructive</topic><topic>Medical care, Cost of</topic><topic>Medicine and Health Sciences</topic><topic>Patient admissions</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Social Sciences</topic><topic>Software</topic><topic>Telemedicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mudiyanselage, Shalika Bohingamu</creatorcontrib><creatorcontrib>Stevens, Jo</creatorcontrib><creatorcontrib>Toscano, Julian</creatorcontrib><creatorcontrib>Kotowicz, Mark A</creatorcontrib><creatorcontrib>Steinfort, Christopher L</creatorcontrib><creatorcontrib>Hayles, Robyn</creatorcontrib><creatorcontrib>Watts, Jennifer J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mudiyanselage, Shalika Bohingamu</au><au>Stevens, Jo</au><au>Toscano, Julian</au><au>Kotowicz, Mark A</au><au>Steinfort, Christopher L</au><au>Hayles, Robyn</au><au>Watts, Jennifer J</au><au>Tsuzuki, Shinya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-06-15</date><risdate>2023</risdate><volume>18</volume><issue>6</issue><spage>e0286533</spage><epage>e0286533</epage><pages>e0286533-e0286533</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The study aims to assess the cost-effectiveness of a personalised telehealth intervention to manage chronic disease in the long run.
The Personalised Health Care (PHC) pilot study was a randomised trial with an economic evaluation alongside over 12 months. From a health service perspective, the primary analysis compared the costs and effectiveness of PHC telehealth monitoring with usual care. An incremental cost-effectiveness ratio was calculated based on costs and health-related quality of life. The PHC intervention was implemented in the Barwon Health region, Geelong, Australia, for patients with a diagnosis of COPD and/or diabetes who had a high likelihood of hospital readmission over 12 months.
When compared to usual care at 12 months, the PHC intervention cost AUD$714 extra per patient (95%CI -4879; 6308) with a significant improvement of 0.09 in health-related quality of life (95%CI: 0.05; 0.14). The probability of PHC being cost-effective by 12 months was close to 65%, at willingness to pay a threshold of AUD$50,000 per quality-adjusted life year.
Benefits of PHC to patients and the health system at 12 months translated to a gain in quality-adjusted life years with a non-significant cost difference between the intervention and control groups. Given the relatively high set-up costs of the PHC intervention, the program may need to be offered to a larger population to achieve cost-effectiveness. Long-term follow-up is required to assess the real health and economic benefits over time.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>37319290</pmid><doi>10.1371/journal.pone.0286533</doi><tpages>e0286533</tpages><orcidid>https://orcid.org/0000-0001-8095-8638</orcidid><orcidid>https://orcid.org/0000-0003-1090-4401</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-06, Vol.18 (6), p.e0286533-e0286533 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2826187450 |
| source | Public Library of Science (PLoS) Journals Open Access; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Biology and Life Sciences Care and treatment Chronic diseases Chronic illnesses Chronic obstructive pulmonary disease Clothing industry Comparative analysis Cost analysis Cost control Costs Customization Diabetes Diabetes mellitus Diagnosis related groups Disease management DRGs Economic analysis Economic aspects Effectiveness Emergency medical care Engineering and Technology Evaluation Health care expenditures Health services Hospital costs Hospitalization Intervention Lung diseases, Obstructive Medical care, Cost of Medicine and Health Sciences Patient admissions Patient outcomes Patients Quality of life Social Sciences Software Telemedicine |
| title | Cost-effectiveness of personalised telehealth intervention for chronic disease management: A pilot randomised controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20personalised%20telehealth%20intervention%20for%20chronic%20disease%20management:%20A%20pilot%20randomised%20controlled%20trial&rft.jtitle=PloS%20one&rft.au=Mudiyanselage,%20Shalika%20Bohingamu&rft.date=2023-06-15&rft.volume=18&rft.issue=6&rft.spage=e0286533&rft.epage=e0286533&rft.pages=e0286533-e0286533&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0286533&rft_dat=%3Cgale_plos_%3EA753093984%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2826187450&rft_id=info:pmid/37319290&rft_galeid=A753093984&rft_doaj_id=oai_doaj_org_article_6c1d1924f89a4202aa884413f4b7e74c&rfr_iscdi=true |